

ASX RELEASE

30 May 2022

Preliminary Final Report and Annual Report – Year Ended 31 March 2022

Amplia Therapeutics Limited (ASX: ATX) today releases the following:

- Appendix 4E Preliminary Final Report YE 31 March 2022
- Annual Report – Year Ended 31 March 2022

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

For Further Information

Dr. John Lambert
Chief Executive Officer
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).